This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Waalkes, T. P. Articles by Aldenderfer, P. Search for Related Content PubMed PubMed Citation Articles by Waalkes, T. P. Articles by Aldenderfer, P.

Carcinoembryonic Antigen for Monitoring Patients with Small Cell Carcinoma of the Lung during Treatment¹

Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 [T. P. W., M. D. A., K. B. W., D. S. E.], and Biological Markers Program, National Cancer Institute, Frederick Cancer Research Center, Frederick, Maryland 21701 [R. W. R., P. A.]

Carcinoembryonic antigen (CEA) was measured at specific intervals in the plasma of 56 patients with small cell carcinoma of the lung. Of these patients, 47 had serial analyses for varying periods during their illness, 42 had pretreatment CEA levels, and 17 of the latter patients had determinations throughout the entire course of their disease. Pretreatment CEA levels were elevated above 2.5 ng/ml for 74% of the 42 patients and above 5.0 ng/ml for 48%. Although exceptions were noted, in general, a direct relationship was found between pretreatment CEA levels and extent of disease or tumor burden. Initial stage of disease, however, was more predictive of survival than was the pretreatment CEA level. With response to therapy, a corresponding decrease in CEA levels occurred for patients with an elevated pretreatment level. For those patients with a pretreatment CEA level below 5.0 ng/ml, an immediate slight increase in level was often seen associated with response and followed by a subsequent fall after one month. A rising CEA level was usually found with recurrence or progression of disease after initial response and occurred frequently prior to clinical evidence of progression. In combination with careful clinical evaluation, serial CEA measurements can aid in assessing tumor changes associated with treatment in patients with small cell carcinoma of the lung particularly at the times of recurrence or disease progression following a partial or complete response.

¹ This study was supported in part by American Cancer Society Grant PDT-108 and by the National Cancer Institute under Contract N01-CA-75380 with Litton Bionetics, Inc.

² To whom requests for reprints should be addressed, at The Johns Hopkins Oncology Center, Room 167, 600 North Wolfe Street, Baltimore, Md. 21205.

Received 4/ 1/80. Accepted 9/ 4/80.

This article has been cited by other articles:

				S. Bandoh, J. Fujita, Y. Ueda, Y. Fukunaga, K. Dohmoto, S. Hojo, Y. Yang, Y. Yamaji, J. Takahara, and T. Ishida Expression of Carcinoembryonic Antigen in Peripheral- or Central-located Small Cell Lung Cancer: Its Clinical Significance Jpn. J. Clin. Oncol., July 1, 2001; 31(7): 305 - 310. [Abstract] [Full Text] [PDF]